GLP-1 agonists: a game changer in pain treatment and addiction

Jul 29, 2025Pain management

GLP-1 drugs may improve pain relief and help with addiction

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer novel analgesia and treat drug-seeking behavior.

GLP-1RAs may play a role in managing pain associated with conditions such as headaches, osteoarthritis, and diabetic neuropathy.
In osteoarthritis, GLP-1RAs could reduce inflammation and cartilage degradation, but more trials are needed in non-obese, non-comorbid patients.
Potential effects of GLP-1RAs in diabetic neuropathy include nerve repair, though optimal dosing and long-term efficacy require further investigation.
Preclinical data indicate that GLP-1RAs may be involved in migraine signaling, but there is a lack of human studies to support this.
Initial trials suggest GLP-1RAs might aid in alcohol addiction, while evidence for their impact on other substances remains unclear.
Significant knowledge gaps exist regarding the effects of GLP-1RAs in pain management and substance use disorders.

AI simplified

Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer novel analgesia and treat drug-seeking behavior. This review examines the role of GLP-1RAs in pain management, focusing on inflammation, macrophage repolarization, oxidative stress, and dopaminergic pathways in substance use disorders. We conducted a literature search in PubMed and Embase (Ovid) from January 2000 to February 2025, identifying studies on GLP-1RA and pain in headaches, osteoarthritis, diabetic neuropathy, and substance use disorders. GLP-1RAs offer a promising shift in pain management, potentially reducing opioid dependence, preventing surgical interventions, and lowering healthcare costs. While early evidence suggests analgesic and disease-modifying effects beyond weight loss, significant knowledge gaps remain. In osteoarthritis, they appear to reduce inflammation and cartilage degradation, but trials in non-obese, non-comorbid patients are needed. In diabetic neuropathy, GLP-1RAs show potential for nerve repair, but optimal dosing and long-term efficacy need clarification. Preclinical data support GLP-1RAs signaling in migraines, but human studies are lacking. Trials in alcohol addiction show promise, though evidence for other substances remains inconclusive. Larger-scale trials are needed to confirm these findings.

Full Text

Full text is available at the source.

View full text ↗

GLP-1 agonists: a game changer in pain treatment and addiction

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief